Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could adding a second diabetes drug early save lives?

NCT ID NCT07566299

Knowledge-focused Sponsor: Chung Shan Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study analyzed health records of over 118,000 adults with obesity, type 2 diabetes, and related heart, kidney, and liver conditions. Researchers compared people who added a second type of diabetes drug (GLP-1 or SGLT2) early to those who did not. The goal was to see if early combination therapy reduces death risk over five years.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
GLP-1 receptor agonist and SGLT2 inhibitor
What this could lead to
If successful, this could show that adding a second diabetes drug early improves survival and reduces heart, kidney, and liver problems in people with obesity and type 2 diabetes.
What could go wrong
This is an observational study using existing health records, not a controlled trial. Results may be affected by unmeasured factors, and the findings need confirmation in prospective studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

118,805 people

The number who actually took part.

Started

Jan 2017

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults will be selected from the TriNetX US Collaborative Network, a distributed database of de-identified electronic health records contributed by participating healthcare organizations across multiple clinical systems and practice settings. The study population consists of adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who received routine clinical care in this network and were identified through diagnosis records, body mass index data, laboratory data, and medication prescribing data. Four mutually exclusive cohorts were defined by background therapy (GLP-1 receptor agonist or SGLT2 inhibitor) and 90-day add-on status, supporting four prespecified pairwise comparisons of early complementary add-on against monotherapy or against usual-care add-on (DPP-4 inhibitor, sulfonylurea, or insulin).

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18 years or older. * BMI ≥27 kg/m², or diagnosis codes consistent with obesity * Type 2 diabetes mellitus * Cardiovascular-kidney-metabolic syndrome stage 2-3 * Metabolic dysfunction-associated steatotic liver disease * New initiation of GLP-1 receptor agonist therapy or SGLT2 inhibitor therapy during the study period as background therapy * No prescription of either GLP-1 receptor agonist or SGLT2 inhibitor within the 6-month washout window before background therapy initiation Exclusion Criteria: * Type 1 diabetes mellitus, or other specified diabetes types that are not type 2 diabetes * Human immunodeficiency virus infection * Other chronic, alcohol-related, or secondary liver diseases * Prior bariatric surgery * Prior solid-organ transplantation * Hepatocellular carcinoma or liver transplant within 1 year before background therapy initiation * Major cardiovascular, kidney, or liver event within the 6-month window before background therapy initiation * Transplant-related complications

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiovascular-kidney-metabolic syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cardiovascular-kidney-metabolic syndrome metabolic dysfunction-associated steatotic liver disease obesity disorder type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiovascular-kidney-metabolic syndrome Metabolic dysfunction-associated steatotic liver disease Obesity type 2 diabetes mellitus

Contacts and locations

Locations

  • Chung Shan Medical University Hospital

    Taichung, Taichung, 402, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.